Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up News

Executive Summary

Noteworthy news from medtech start-ups. This month we profile Ibris, which is developing prognostics to identify breast cancer patients in need of chemotherapy, and Delphinus Medical Technologies, whose platform enables 3-D full breast ultrasound.

You may also be interested in...



Report From RSNA: Interest Expands In Breast Imaging Market

Several new modalities are poised to change the way breast cancer screenings and diagnostics are performed as physicians and patients continue to search for technologies that can do more than standard X-rays. Ultrasound, computed tomography, and 3-D imaging are being touted as ways to improve the detection of tumors – especially in women with dense breast tissue – as well as to reduce exposure to radiation. Currently, the market is dominated by large, established manufacturers, but some new players are bringing in innovative options that are poised to push the field forward.

The Evolving World Of Breast Cancer Management

The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.

Frontiers in Breast Cancer Research, Part II: Developments in Partial Breast Irradiation and Tumor Ablation

As the use of breast conserving lumpectomy expands as a treatment for early-stage breast cancer, interest has surged in alternatives to whole breast irradiation. Follow-on radiation treatment is crucial to the success of this therapy, but a significant number of women are either unable or unwilling to undergo the typical treatment course involving five to seven weeks of daily radiation therapy. The device industry is responding with technologies aimed at delivering post-lumpectomy radiation therapy in a more convenient, potentially safer way.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel